Regulatory approval

Published by the Health Service Executive. Approved

Neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pertuzumab/Trastuzumab - ODMS; Carboplatin and Cisplatin - N/A

Citation

Pertuzumab and Trastuzumab (Phesgo), PACLitaxel and CARBOplatin Therapy (TRAIN-2), 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6442/790_v3_Phesgo_PACLitaxel_CARBOplatin.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2022-12-20	Health Service Executive	Indication approved for reimbursement.